Latest Pharma Insights
CRN Urges White House To Leave Dietary Ingredients Uncovered By Blanket Tariffs Order
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
Kailera IPO Is Biggest So Far In 2026, May Become Biopharma’s Largest In The US
The obesity drug developer grossed $625m and could bring in $718.8m upon closing, beating Sana Biotechnology’s $675.6m IPO in 2021 and Bausch + Lomb’s $711.9m offering in 2022.
Scrip - April 17, 2026
The obesity drug developer grossed $625m and could bring in $718.8m upon closing, beating Sana Biotechnology’s $675.6m IPO in 2021 and Bausch + Lomb’s $711.9m offering in 2022.
Scrip - April 17, 2026
Finance Watch: Oricell, Terremoto, Neomorph Raise Venture Mega-Rounds
Private Company Edition: Oricell raised $110m in a pre-IPO round, Terremoto closed a $108m series C financing and Neomorph completed a $100m series B, but all three rounds were slightly smaller than the companies’ prior financings. Also, Adcendo raised $75m for its ADC programs.
Scrip - April 17, 2026
Private Company Edition: Oricell raised $110m in a pre-IPO round, Terremoto closed a $108m series C financing and Neomorph completed a $100m series B, but all three rounds were slightly smaller than the companies’ prior financings. Also, Adcendo raised $75m for its ADC programs.
Scrip - April 17, 2026
UCB Looks To Bolster Its Epilepsy Pipeline With Neurona Buyout
The Belgian specialty pharma will pay $650m up front to acquire privately held Neurona and its lead cell therapy candidate, NRTX-1001.
Scrip - April 17, 2026
The Belgian specialty pharma will pay $650m up front to acquire privately held Neurona and its lead cell therapy candidate, NRTX-1001.
Scrip - April 17, 2026
MeiraGTx Brings Rare Eye Disease Gene Therapy Back Home
Deal Snapshot: Despite missing its primary goal in a Phase III trial, MeiraGTx intends to move quickly towards global regulatory submissions for the XLRP gene therapy bota-vec which it has reacquired from long-time partner J&J.
Scrip - April 17, 2026
Deal Snapshot: Despite missing its primary goal in a Phase III trial, MeiraGTx intends to move quickly towards global regulatory submissions for the XLRP gene therapy bota-vec which it has reacquired from long-time partner J&J.
Scrip - April 17, 2026
Lupin Follows Sandoz, Sun In Antitrust Suit Settlement; $30m For Humana
Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation on alleged price-fixing. This $30m settlement with US insurance giant Humana denies all allegations and does not imply admission of liability, but could more settlements be in the offing?
Scrip - April 17, 2026
Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation on alleged price-fixing. This $30m settlement with US insurance giant Humana denies all allegations and does not imply admission of liability, but could more settlements be in the offing?
Scrip - April 17, 2026
Freya Lines Up FB301 Phase II Push After Promising Early Stage Data
The firm's microbiome-based therapy is poised for Phase II development as it targets a market with limited treatment options.
Scrip - April 17, 2026
The firm's microbiome-based therapy is poised for Phase II development as it targets a market with limited treatment options.
Scrip - April 17, 2026
Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals
Join our Japan-based team for an audio roundup of key developments in the country's biopharma industry over the first few months of this year.
Scrip - April 17, 2026
Join our Japan-based team for an audio roundup of key developments in the country's biopharma industry over the first few months of this year.
Scrip - April 17, 2026
Tarver Takes Home Health Case To AAMI
CDRH director Michelle Tarver used an AAMI keynote to spotlight the FDA's home-health push — including the TEMPO pre-market pilot and the READI-Home hospital readmissions challenge — while also updating attendees on digital health, planned interoperability guidance, and new hiring.
Medtech Insight - April 18, 2026
CDRH director Michelle Tarver used an AAMI keynote to spotlight the FDA's home-health push — including the TEMPO pre-market pilot and the READI-Home hospital readmissions challenge — while also updating attendees on digital health, planned interoperability guidance, and new hiring.
Medtech Insight - April 18, 2026
CRN Urges White House To Leave Dietary Ingredients Uncovered By Blanket Tariffs Order
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
Hikma Hits Back Over Amarin’s ‘Strawman’ Induced Infringement Claims
As Amarin and Hikma continue to file briefs with the Supreme Court ahead of oral arguments at the end of this month in their skinny-label induced-infringement litigation over carve-outs for generic Vascepa (icosapent ethyl), the latest development sees Hikma attacking Amarin’s 'safe harbor' claims.
Generics Bulletin - April 17, 2026
As Amarin and Hikma continue to file briefs with the Supreme Court ahead of oral arguments at the end of this month in their skinny-label induced-infringement litigation over carve-outs for generic Vascepa (icosapent ethyl), the latest development sees Hikma attacking Amarin’s 'safe harbor' claims.
Generics Bulletin - April 17, 2026
Mabwell Finds A Denosumab Biosimilar Partner In Malaysia
Mabwell has signed a Malaysian licensing deal for its denosumab biosimilars Mailishu and Maiweijian, further expanding its footprint in Southeast Asia.
Generics Bulletin - April 17, 2026
Mabwell has signed a Malaysian licensing deal for its denosumab biosimilars Mailishu and Maiweijian, further expanding its footprint in Southeast Asia.
Generics Bulletin - April 17, 2026
Amneal Builds Scale In US Drug-Device Respiratory Market
Amneal has launched its first US metered-dose inhalers, introducing generics to ProAir and legacy QVAR products as legal wins, patent scrutiny, and regulatory shifts further open a long-protected respiratory market.
Generics Bulletin - April 17, 2026
Amneal has launched its first US metered-dose inhalers, introducing generics to ProAir and legacy QVAR products as legal wins, patent scrutiny, and regulatory shifts further open a long-protected respiratory market.
Generics Bulletin - April 17, 2026
Mochida Chases Gap In Japanese IVF Biosimilars
Mochida has partnered with Qilu Pharmaceutical to develop and commercialize a follitropin alfa IVF biosimilar in Japan, marking its entry into reproductive medicine biosimilars and targeting an underpenetrated but growing fertility market.
Generics Bulletin - April 17, 2026
Mochida has partnered with Qilu Pharmaceutical to develop and commercialize a follitropin alfa IVF biosimilar in Japan, marking its entry into reproductive medicine biosimilars and targeting an underpenetrated but growing fertility market.
Generics Bulletin - April 17, 2026
Healthtech Start-Ups Set The Tone At BioWales ’26
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026